Gilead's Genvoya wins EC nod; Valeant's problems weighing on share prices of Horizon, Mallinckrodt;

@FiercePharma: CBN: Multinational drugmakers face uphill battle in China. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: UPDATED: Pfizer finally gets its inversion with $160B Allergan megamerger agreement. Article | Follow @CarlyHFierce

> Gilead's ($GILD) 4-in-1 HIV treatment has won approval from the European Commission. Release

> Purdue Pharma, Johnson & Johnson ($JNJ), Endo ($ENDP), Allergan ($AGN) and Teva ($TEVA) have responded to the City of Chicago's second attempt to sue pain drugmakers for the costs of what Chicago says is a drug addiction epidemic. Report

> The questions that have led to the dramatic slide in the price of Valeant Pharmaceuticals' ($VRX) shares have taken a toll on the share of other companies such as Horizon Pharma ($HZNP) and Mallinckrodt ($MNK), companies often compared to Valeant. Story

> A Harvard-led panel of experts called the WHO response to the Ebola outbreak an "egregious failure." Report

> Bristol-Myers Squibb has added hep C drug Daklinza (daclatasvir) to the Medicines Patent Pool, allowing generic makers to produce it royalty free in low-income middle income countries. Release

Medical Device News

@FierceMedDev: ICYMI Friday: Bard to buy Liberator for $181M to improve access to home care market. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Boston Scientific earns CE mark for second-gen Watchman implant to prevent stroke. More | Follow @VarunSaxena2

@EmilyWFierce: ICYMI Friday: Cancer diagnostics company closes up shop after 6-year FTC investigation. Article | Follow @EmilyWFierce

> Startup gets $36.5M to conduct U.S. pivotal trial for novel endoscopic weight loss device. More

> CardioDiagnostics gets in on patient monitoring with plans for $7M fundraise. Article

> Mindray Medical shells out $25M to settle pulse oximeter patent battle with Masimo. Story

Biotech News

@FierceBiotech: With Pfizer and Allergan set for a $160B megamerger, what becomes of R&D? Report | Follow @FierceBiotech

@JohnCFierce: So Ian Read remains CEO. Gets $AGN at a pretty decent price, Gets his Irish domicile. Looking for $2B in cuts. Read must be pretty chuffed. | Follow @JohnCFierce

@DamianFierce: I thought Ian Read would be taller. Item | Follow @DamianFierce

> Roche's blockbuster-hopeful immunotherapy shows promise in skin cancer. Report

> ObsEva taps A-list investors for $60M as pipeline nears late-phase trials. Article

Animal Health News

> Virginia Tech preps dog trial of new method to improve glioblastoma treatment. Report

> Zoetis ups the ante in prevention with new flu vaccine and flea fighter for dogs. More

> Oasmia chairman is optimistic about animal health despite downsized IPO. Story

> Kuddly joins herd of veterinary apps with $1.5M seed round. Item

> Taco Bell joins fast food peers with cage-free egg pledge. Article

Biotech IT News

> Molecular Health raises $27M to advance data-crunching tech. News

> Illumina to make 5,000-genome autism database available through BaseSpace. Report

> Amazon shares landmark cancer genome data sets on cloud platform. Story

> FDA gives scientists freedom to tweet in long-awaited social media policy. Item

> AstraZeneca inks deal to install robots at new R&D facility. Article

Pharma Marketing News

> Amgen nabs another PCSK9 exclusive, this time with giant CVS. Report

> Better together? Savvy e-patients may make pharma marketing smarter. Story

> Teva goes for laughs in new social media campaign for COPD. Item

> AstraZeneca aims at a 'broader' target with services-based lung cancer effort. Article

> Healthcare ad and media agencies break into annual 'best workplaces' ranking. More

Suggested Articles

UnitedHealthcare will stop covering Descovy in PrEP in favor of Truvada, which is on track to see low-cost generic competition in September.

AstraZeneca has signed into the EU’s first finalized COVID-19 vaccine supply agreement.  

The U.K.'s two new deals with J&J and Novavax bring its stockpile of potential COVID-19 vaccines to 340 million doses while expanding clinical trials.